The DOI matches its Crossref record.
Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties
Abstract
An anticancer agent of intermediate molecular weight and having both a hydrophilic and hydrophobic nature was developed by utilizing the antitumor protein neocarzinostatin (NCS; Mr = 12000) as a prototype drug. The modification was achieved by reacting the two amino groups on NCS with an anhydride group of partially half-esterified (p-E-) or partially hydrolyzed (p-H-) poly(styrene-co-maleic anhydride) (SMA) in 0.8 M NaHCO3. The SMA samples with narrow molecular weights distributions (Mw = ca. 2000) were prepared by copolymerizing styrene and maleic anhydride in cumene followed by fractionation by means of a column-elution method. The derivatives p-E- or p-H-SMA were then formed by using the appropriate monoalcohols or H2O, respectively. These SMA derivatives contain about 2 mol of anhydride residues/mol of SMA. The reaction product, SMA-conjugated NCS (designated as SMANCS), was purified by dialysis followed by gel filtration with Sephadex G-75. The complete reaction yielded essentially a single product, biantennary SMANCS. The molecular weight of the pure SMAMCS was estimated by various methods, including polyacrylamide gel electrophoresis with NaDodSO4, HPLC in the gel permeation mode, fluorescence polarization, and a decrease in both nitrogen and protein contents. These results agree with the apparent molecular weight of about 16000. Characters of SMANCS was considerably altered from that of parental NCS: solubility characteristics in both organic and aqueous solvents were changed, the biological half-life in blood was prolonged 10 times, and antitumor activity became more pronounced, but the toxicity was reduced to one-fourth of the parental NCS. Thus, the present study has provided a method of improving biologically active substances by polymer conjugation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Self-citationMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Self-citationTargeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Self-citationMaeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
Self-citationNichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814
Self-citationControlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Self-citationPolymer nanogels: A versatile nanoscopic drug delivery platform
Chacko, R. T., Ventura, J., Zhuang, J., & Thayumanavan, S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.02.002 · Cited by 645
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
Self-citationOxygen Radicals in Influenza-Induced Pathogenesis and Treatment with Pyran Polymer-Conjugated SOD
Oda, T., Akaike, T., Hamamoto, T., Suzuki, F., Hirano, T., & Maeda, H. (1989) · Science · doi:10.1126/science.2543070 · Cited by 418
Self-citationGünay, K. A., Theato, P., & Klok, H. (2013) · Journal of Polymer Science Part A: Polymer Chemistry · doi:10.1002/pola.26333 · Cited by 399
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates
Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00280-7 · Cited by 374
Maeda, H., Tsukigawa, K., & Fang, J. (2016) · Microcirculation · doi:10.1111/micc.12228 · Cited by 336
Self-citationMultifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
Targeted Drug Delivery in Cancer Therapy
Vasir, J. K., & Labhasetwar, V. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400405 · Cited by 327
MAEDA, H. (2012) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.88.53 · Cited by 291
Self-citationPerspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., & Maeda, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00002 · Cited by 278
Self-citation
Metadata
- Authors
- Maeda, H., Ueda, M., Morinaga, T., & Matsumoto, T.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1985-04
- Volume
- 28
- Issue
- 4
- Pages
- 455-461
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1972992205
- Cited by
- 225
- References
- 0
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.